June 29, 2018
Emerging CAR-T immunotherapies leverage modified versions of patient’s T-cells to target and kill cancer cells. In a new study, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also…
February 19, 2020
UC San Diego bioengineers developed a control system that could make CAR T-cell therapy safer and more powerful when treating cancer. By programming CAR T cells to switch on when exposed to blue light, the researchers controlled the cells to destroy skin tumors in mice without harming healthy tissue
August 28, 2017
…of Medicine have discovered that drugs that activate the cells’ proteasome, or recycling center, tip the balance in favor of memory CD8+ T cells. This approach could be used to improve how well vaccines and immunotherapies work and how long they last.
October 15, 2019
UC San Diego bioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells.
June 11, 2020
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
April 2, 2015
Cells of the intestine, liver and pancreas are difficult to produce from stem cells. Writing in Cell Stem Cell April 2, researchers at University of California, San Diego School of Medicine have discovered that chromosomes in laboratory stem cells open slowly over time, in the same sequence that occurs during…
August 12, 2021
A new cancer immunotherapy pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue. The approach could make chimeric antigen receptor (CAR) T-cell therapy safer and effective at treating solid tumors.
January 10, 2013
…differences and similarities between two types of hESC-derived endocrine cell populations and primary human endocrine cells, with the longer-term goal of developing new stem cell therapies for diabetes.
July 3, 2012
…the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease. One such type of cancer is called pediatric T cell acute lymphoblastic leukemia, or…
June 3, 2021
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
